Sickle Cell Disease Trial, Recruiting NCT06477289 Sponsor: St. Jude Children's Research Hospital Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT06477289
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with sickle cell disease (any type)
  • You are already a participant in the Sickle Cell Clinical Research and Intervention Program
  • You are between 12 and 25 years old at the time of joining the trial
  • English is your main language
  • You have access to a device (such as a phone, tablet, or computer) with WiFi

Who may not be able to join:

  • You have a history of an intellectual disability
  • You have had a traumatic brain injury or have a seizure disorder (such as epilepsy)
  • You have had a stroke
  • You are currently receiving a treatment intended to cure sickle cell disease, such as a stem cell transplant or gene therapy
  • You are currently taking prescribed medication or receiving treatment for a sleep disorder
  • You or your legal guardian are unable or unwilling to sign a written consent form to take part in research

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrew Heitzer, Phd, St. Jude Children's Research Hospital

Phone: 888-226-4343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
St. Jude Children's Research Hospital
Registry
ClinicalTrials.gov
Start date
16 September 2024
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Evaluate the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (working memory and verbal comprehension) in individuals (ages 12-25) diagnosed with sickle cell disease.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov